ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 5124 for:    reach 2

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease (Reach2HD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01590888
Recruitment Status : Completed
First Posted : May 3, 2012
Results First Posted : July 18, 2016
Last Update Posted : July 18, 2016
Sponsor:
Information provided by (Responsible Party):
Prana Biotechnology Limited

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition Huntington Disease
Interventions Drug: PBT2
Drug: Placebo
Enrollment 109

Recruitment Details Twenty sites were initiated for the study, with participants enrolled at 14 sites in the US and 5 sites in Australia.
Pre-assignment Details  
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description PBT2: 250mg capsules administered orally once per day for 26 weeks PBT2: 100mg capsules administered orally once per day for 26 weeks Placebo: Matching capsules administered orally once per day for 26 weeks
Period Title: Overall Study
Started 36 38 35
Completed 32 38 34
Not Completed 4 0 1
Reason Not Completed
Adverse Event             3             0             1
Lost to Follow-up             1             0             0
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill Total
Hide Arm/Group Description PBT2: 250mg capsules administered orally once per day for 26 weeks PBT2: 100mg capsules administered orally once per day for 26 weeks Placebo: Matching capsules administered orally once per day for 26 weeks Total of all reporting groups
Overall Number of Baseline Participants 36 38 35 109
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 36 participants 38 participants 35 participants 109 participants
50.3  (10.4) 54.1  (12.1) 51.2  (10.4) 51.9  (11.0)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 36 participants 38 participants 35 participants 109 participants
Female
17
  47.2%
19
  50.0%
19
  54.3%
55
  50.5%
Male
19
  52.8%
19
  50.0%
16
  45.7%
54
  49.5%
Ethnicity (NIH/OMB)  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 36 participants 38 participants 35 participants 109 participants
Hispanic or Latino
2
   5.6%
0
   0.0%
0
   0.0%
2
   1.8%
Not Hispanic or Latino
34
  94.4%
38
 100.0%
35
 100.0%
107
  98.2%
Unknown or Not Reported
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Race (NIH/OMB)  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 36 participants 38 participants 35 participants 109 participants
American Indian or Alaska Native
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Asian
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Native Hawaiian or Other Pacific Islander
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Black or African American
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
White
35
  97.2%
38
 100.0%
35
 100.0%
108
  99.1%
More than one race
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Unknown or Not Reported
1
   2.8%
0
   0.0%
0
   0.0%
1
   0.9%
Region of Enrollment  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 36 participants 38 participants 35 participants 109 participants
United States 26 28 25 79
Australia 10 10 10 30
Body Mass Index  
Mean (Standard Deviation)
Unit of measure:  Kg/m^2
Number Analyzed 36 participants 38 participants 35 participants 109 participants
25.51  (4.89) 25.40  (4.53) 27.09  (6.03) 25.98  (5.18)
Total Function Capacity   [1] 
Mean (Standard Deviation)
Unit of measure:  Units on a scale
Number Analyzed 36 participants 38 participants 35 participants 109 participants
9.1  (2.2) 9.3  (2.3) 9.3  (1.6) 9.2  (2.0)
[1]
Measure Description: Total function capacity (TFC) is a scale measuring the participants capacity to perform 5 areas - their capacity to work, capacity to handle financial affairs, capacity to manage domestic responsibilities, capacity to perform activities of daily living and level of care required (home or care facility). The scale used is a TOTAL of each of the 5 areas, which range from 0 (unable to perform or require full care) to either 2 or 3 (normal, no assistance required). The TFC can scored from 0 to 13. The lower the score, the more severe the disease state of Huntington disease is.
CAG Larger Allele Repeat Length   [1] 
Mean (Standard Deviation)
Unit of measure:  CAG repeats
Number Analyzed 36 participants 38 participants 35 participants 109 participants
44.4  (4.6) 43.2  (2.8) 44.1  (3.9) 43.9  (3.8)
[1]
Measure Description: Huntington disease (HD) is a dominant genetic disorder. Mutations in the HTT gene cause HD. The HTT mutation involves a DNA segment known as a Cytosine, Adenine and Guanine (CAG) trinucleotide repeat, a series of three DNA building blocks. Normally, the CAG segment is repeated 10 to 35 times within the gene. In people with HD, the CAG segment is repeated more than 36 times with higher repeat numbers normally indicating earlier onset of the disease and increased severity of symptoms.
CAG Smaller Allele Repeat Length   [1] 
Mean (Standard Deviation)
Unit of measure:  CAG repeats
Number Analyzed 36 participants 38 participants 35 participants 109 participants
18.8  (4.4) 18.5  (3.0) 20.0  (4.8) 19.1  (4.1)
[1]
Measure Description:

Huntington disease (HD) is a dominant genetic disorder. Mutations in the HTT gene cause HD. The HTT mutation involves a DNA segment known as a Cytosine, Adenine and Guanine (CAG) trinucleotide repeat, a series of three DNA building blocks. Normally, the CAG segment is repeated 10 to 35 times within the gene. In people with HD, the CAG segment is repeated more than 36 times with higher repeat numbers normally indicating earlier onset of the disease and increased severity of symptoms.

HD is a dominant genetic disorder.

Disease Burden   [1] 
Mean (Standard Deviation)
Unit of measure:  CAG repeats*years
Number Analyzed 36 participants 38 participants 35 participants 109 participants
411.68  (104.96) 392.54  (96.10) 410.07  (110.02) 404.49  (103.06)
[1]
Measure Description: Disease burden in patients with Huntington disease is calculated by (CAG repeat length - 35) x Age at Baseline, with the higher score indicating a greater Disease Burden for a patient.
1.Primary Outcome
Title Safety and Tolerability of PBT2 in Patients With HD
Hide Description As measured by the total number of participants in each dose group who reported at least one adverse events during the study,
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
Safety population as defined as all participants who received at least one dose of study drug.
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 36 38 35
Measure Type: Number
Unit of Measure: participants
32 30 28
2.Secondary Outcome
Title Change From Baseline in Cognitive Test Battery - Composite z Scores
Hide Description Cognition composite z-scores were calculated for each participant. The composite scores were defined as the mean of the individual z-scores for the various cognition assessments. The Main Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test and Stroop Word Reading Test. The Exploratory Composite z-score was calculated for Category Fluency Test, Trail Making Test Part B, Map Search, Symbol Digit Modalities Test, Stroop Word Reading Test and Speeded Tapping test. The Executive Function Composite z-score was calculated from Category Fluency Test and Trail Making Test Part B. There is no unit of measure for the z score as it is the pure number calculated from the SD from the mean. A higher z score indicates an improvement.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
Intent to Treat
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 32 38 34
Mean (Standard Deviation)
Unit of Measure: z score
Main Composite z-score 0.0592  (0.2670) -0.0413  (0.3170) -0.0194  (0.2374)
Exploratory Composite z-score 0.0530  (0.2568) -0.0287  (0.3349) -0.0144  (0.2331)
Executive Function z-score 0.2274  (0.4288) -0.1026  (0.4771) 0.0553  (0.3385)
3.Secondary Outcome
Title Change From Baseline in Motor Function
Hide Description Total motor score calculated from the Unified Huntington Disease Rating Scale - Motor Function. The motor section of the UHDRS assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor impairment scores is the sum of all the individual motor ratings, with higher scores indicating more severe motor impairment than lower scores. A maximum score of 60 is possible (range 0-60).
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
Intent to Treat population analysed, and defined as all participants who received at least one dose of study and underwent at least one post baseline efficacy assessment.
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 34 38 35
Mean (Standard Deviation)
Unit of Measure: units on a scale
-0.7  (7.6) 1.3  (9.0) -1.3  (7.3)
4.Secondary Outcome
Title Change From Baseline in Functional Abilities
Hide Description

Total Functional Capacity (TFC) assessment was based on an individual's ability to perform common daily tasks. TFC score range was 0 to 13.

Higher scores on the function scales indicate better functioning than lower scores.

Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
Intent to Treat Population analysed
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 34 38 35
Mean (Standard Deviation)
Unit of Measure: units on a scale
1.1  (1.0) 1.3  (1.0) 1.3  (0.9)
5.Secondary Outcome
Title Change From Baseline in Behaviour
Hide Description Total Behavioural score from the Unified Huntington Disease Rating Scale. The behavioural assessment measures the frequency and severity of symptoms related to affect, thought content and coping styles. The total behaviour score is the sum of all responses, with scale range of 0 to 8. Higher scores on the behaviour assessments indicate more severe disturbance than lower scores.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
Intent to Treat population analysed
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 34 38 35
Mean (Standard Deviation)
Unit of Measure: units on a scale
-2.3  (9.2) 3.0  (15.9) 0.7  (13.0)
6.Secondary Outcome
Title Change From Baseline in Investigator Global Assessments by Efficacy Index
Hide Description Global function was assessed by the Investigator using the clinical global impression (CGI) scale which included assessing the severity of illness and global improvement and calculating the efficacy index for each participant. The efficacy index aims to relate therapeutic effects to reported side effects as assessed by the Investigator (range from 0 [marked improvement and no side effects] to 4 [unchanged or worse] and side effects outweigh therapeutic effects) and is calculated for each participant by dividing the therapeutic effect score by the side effects score. An improvement is reflected by CGI scale Efficacy Index values >1.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
Intent to Treat
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 32 38 34
Mean (Standard Deviation)
Unit of Measure: ratio
1.313  (0.592) 1.276  (0.654) 1.176  (0.459)
7.Secondary Outcome
Title Change From Baseline in Blood Biomarkers
Hide Description Biomarkers assessed primarily with mutant huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
ITT population
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 32 38 34
Mean (Standard Deviation)
Unit of Measure: ratio
1.97  (24.39) 0.14  (4.70) -1.72  (9.72)
8.Secondary Outcome
Title Change From Baseline in Brain Function (MRI)
Hide Description Measure of whole brain iron concentrations.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
ITT population. MRI was performed at one site only, resulting in a subset of participants available for analysis.
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 2 1 2
Mean (Standard Deviation)
Unit of Measure: mm^3
0.0029  (0.0043) 0.0067 [1]   (NA) 0.0098  (0.0115)
[1]
Not applicable with an n equalling 1.
9.Secondary Outcome
Title Change From Baseline in Blood Biomarkers
Hide Description Biomarkers assessed primarily with soluble huntingtin protein, normalised to lysate protein concentrations, as a change from baseline.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
ITT population
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 23 27 28
Mean (Standard Deviation)
Unit of Measure: mg/mL
-3.18  (8.23) -2.09  (5.44) -3.07  (5.98)
10.Secondary Outcome
Title Change From Baseline in Blood Biomarkers - Selenium
Hide Description Biomarkers assessed primarily with plasma selenium as a change from baseline.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
ITT population
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 32 35 33
Mean (Standard Deviation)
Unit of Measure: ug/L
1.3  (28.1) -6.3  (18.2) 2.0  (20.5)
11.Secondary Outcome
Title Change From Baseline in Urine Biomarkers
Hide Description Biomarkers assessed primarily with 8-hydroxy-2'-deoxyguanosine, normalised to creatinine concentrations, as a change from baseline.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
ITT population
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 30 38 33
Mean (Standard Deviation)
Unit of Measure: ng/mL
-0.4258  (1.3383) 0.0832  (2.0456) 35.5302  (208.5614)
12.Secondary Outcome
Title Change From Baseline in Brain Function (MRI)
Hide Description Measure of the structural brain volume as assessed by the left caudate volume.
Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
ITT population. MRI was performed at one site only, resulting in a subset of participants available for analysis.
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 2 2 2
Mean (Standard Deviation)
Unit of Measure: mm^3
50.0  (70.7) 27.5  (94.0) -170.5  (67.2)
13.Secondary Outcome
Title Change From Baseline in Cognitive Test Battery - TMT Part B
Hide Description

Trail Making Test Part B was assessed by the number of seconds to complete the test (from 0 to 240 seconds).

The Trails Making Test Part B actual change from baseline at Week 26 was analysed.

Time Frame Baseline to 26 weeks
Show Outcome Measure DataHide Outcome Measure Data
Hide Analysis Population Description
Intent to Treat
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description:
PBT2: 250mg capsules administered orally once per day for 26 weeks
PBT2: 100mg capsules administered orally once per day for 26 weeks
Placebo: Matching capsules administered orally once per day for 26 weeks
Overall Number of Participants Analyzed 32 38 34
Mean (Standard Deviation)
Unit of Measure: seconds
-6.3  (30.0) 12.8  (43.3) 8.9  (28.7)
Time Frame Reported AEs from time of consent to end of study (Week 30 or 4 weeks post cessation of study drug).
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title PBT2 250mg PBT2 100mg Sugar Pill
Hide Arm/Group Description PBT2: 250mg capsules administered orally once per day for 26 weeks PBT2: 100mg capsules administered orally once per day for 26 weeks Placebo: Matching capsules administered orally once per day for 26 weeks
All-Cause Mortality
PBT2 250mg PBT2 100mg Sugar Pill
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   --/--      --/--      --/--    
Show Serious Adverse Events Hide Serious Adverse Events
PBT2 250mg PBT2 100mg Sugar Pill
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   5/36 (13.89%)      2/38 (5.26%)      1/35 (2.86%)    
Cardiac disorders       
Acute Coronary Syndrome * 1  1/36 (2.78%)  1 0/38 (0.00%)  0 0/35 (0.00%)  0
Congenital, familial and genetic disorders       
Worsening of Huntington Disease * 1  1/36 (2.78%)  1 0/38 (0.00%)  0 0/35 (0.00%)  0
Stabilisation of Huntington Disease * 1  0/36 (0.00%)  0 1/38 (2.63%)  1 0/35 (0.00%)  0
Infections and infestations       
Viral Infection * 1  1/36 (2.78%)  1 0/38 (0.00%)  0 0/35 (0.00%)  0
Pneumonia * 1  1/36 (2.78%)  1 0/38 (0.00%)  0 0/35 (0.00%)  0
Injury, poisoning and procedural complications       
Fall * 1  0/36 (0.00%)  0 1/38 (2.63%)  1 0/35 (0.00%)  0
Psychiatric disorders       
Psychotic Depression * 1  1/36 (2.78%)  1 0/38 (0.00%)  0 0/35 (0.00%)  0
Suicide Attempt * 1  1/36 (2.78%)  1 1/38 (2.63%)  1 0/35 (0.00%)  0
Aggression * 1  0/36 (0.00%)  0 0/38 (0.00%)  0 1/35 (2.86%)  1
*
Indicates events were collected by non-systematic assessment
1
Term from vocabulary, MedDRA 15.1
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
PBT2 250mg PBT2 100mg Sugar Pill
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   3/36 (8.33%)      3/38 (7.89%)      2/35 (5.71%)    
Congenital, familial and genetic disorders       
Huntington disease * 1  1/36 (2.78%)  1 3/38 (7.89%)  3 0/35 (0.00%)  0
Gastrointestinal disorders       
Constipation * 1  2/36 (5.56%)  2 3/38 (7.89%)  3 0/35 (0.00%)  0
Dry mouth * 1  3/36 (8.33%)  3 1/38 (2.63%)  1 0/35 (0.00%)  0
General disorders       
Gait disturbance * 1  1/36 (2.78%)  1 2/38 (5.26%)  2 0/35 (0.00%)  0
Infections and infestations       
Influenza * 1  1/36 (2.78%)  1 2/38 (5.26%)  2 0/35 (0.00%)  0
Musculoskeletal and connective tissue disorders       
Myalgia * 1  2/36 (5.56%)  3 3/38 (7.89%)  3 0/35 (0.00%)  0
Muscolskeletal stiffness * 1  0/36 (0.00%)  0 0/38 (0.00%)  0 2/35 (5.71%)  2
Nervous system disorders       
Paraesthesia * 1  0/36 (0.00%)  0 0/38 (0.00%)  0 2/35 (5.71%)  2
Psychiatric disorders       
Depression * 1  2/36 (5.56%)  2 3/38 (7.89%)  3 0/35 (0.00%)  0
Renal and urinary disorders       
urinary incontinence * 1  0/36 (0.00%)  0 0/38 (0.00%)  0 2/35 (5.71%)  2
Skin and subcutaneous tissue disorders       
Rash * 1  0/36 (0.00%)  0 0/38 (0.00%)  0 2/35 (5.71%)  2
*
Indicates events were collected by non-systematic assessment
1
Term from vocabulary, MedDRA 15.1
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title: Dr Caroline Herd
Organization: Prana Biotechnology
Phone: +61393494906
Responsible Party: Prana Biotechnology Limited
ClinicalTrials.gov Identifier: NCT01590888     History of Changes
Other Study ID Numbers: PBT2-203
First Submitted: April 18, 2012
First Posted: May 3, 2012
Results First Submitted: November 17, 2015
Results First Posted: July 18, 2016
Last Update Posted: July 18, 2016